On August 4th, 2023, the US Food and Drug Administration approved the first oral medication for Postpartum Depression in adults.
The drug, Zurzuvae (zuranolone), has been tested through two randomized, double-blinded, placebo-controlled, multicenter studies.
"Patients in the Zurzuvae groups showed significantly more improvement in their symptoms compared to those in the placebo groups. The treatment effect was maintained at Day 42—four weeks after the last dose of Zurzuvae."
The drug is not yet approved by Health Canada, however, it's potential has generated hope and optimism for the treatment of postpartum depression in coming years.
To read the full press release from the U.S. FDA, see the link below: